InvestLog
Back to Market返回行情

MAIA MAIA Biotechnology, Inc.

AMEXHealthcare
$1.44-1.37%ClosedMarket Cap: $87.6M

As of 2026-07-10 16:00

Why MAIA matters now

MAIA Biotechnology, Inc. (MAIA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.44 with -1.37% on the session and $87.6M in market capitalization.

The latest indexable market news headline is "MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial" from GlobeNewsWire.

Latest News

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialGlobeNewsWire · 2026-07-08
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialGlobe News Wire · 2026-07-08
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung CancerGlobeNewsWire · 2026-06-25
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory UniversityGlobeNewsWire · 2026-06-18
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion TrialGlobe News Wire · 2026-06-10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

AMEX

Beta

0.23

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.